| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 0.0 | 0.0 |
| Net income | -85.8 | -57.5 |
| EPS (diluted, $ a share) | $-0.76 | $-0.65 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: IMNM. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Immunome Inc.: key numbers
- Share price
- $17.61Close, Nov 16
- Market cap
- $2.08B
- Shares outstanding
- 118.07MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Immunome Inc.
All →Immunome Financial Results
Immunome reported third quarter 2026 financial results and provided a pipeline update, highlighting an FDA PDUFA date of April 28, 2027, for varegacestat. The company also announced IND clearance for its solid tumor ADC candidate IM-1340 and plans to initiate a Phase 1 trial by year-end 2026.
- Term
- Q3 2026
“We made significant progress across our oncology pipeline in recent months. We continue to advance varegacestat toward approval and launch, with an FDA PDUFA date of April 28, 2027, and recent EMA validation of our MAA. Beyond varegacestat, we now have three programs in the clinic, with IM-1340 expected to become the fourth by year-end. We are progressing the Phase 1 study of IM-1021, our ROR1-targeted ADC, and look forward to presenting updated Phase 1 data at ASH in December.”
Clay B. Siegall, Ph.D., President and Chief Executive Officer of Immunome
Immunome Other 8-K Filing
Immunome entered into an amendment with Bristol-Myers Squibb (BMS) to eliminate all future milestone and royalty payment obligations related to varegacestat and AL101. In exchange, Immunome paid BMS $20 million in cash and issued approximately 4.4 million shares of common stock, while also gaining full ownership of the related patent rights.
- Counterparty
- Bristol-Myers Squibb Company